'Stranger Things' ushered in a new era for Netflix

A lot has changed since its first season in 2016, as Netflix has announced dozens of "Stranger Things" partnerships and collaborations with brands....

Disney's 'Zootopia 2' to hit $1 billion box office, only the second Hollywood film to do so this year

Disney Animation's "Zootopia 2" is set to cross the billion-dollar box-office mark on Friday, becoming the second Hollywood film to reach the benchmark in 2025....

Rivian's AI, autonomy impress Wall Street, but EV and capital concerns remain

Rivian impressed Wall Street with its plans for AI and automation, but significant challenges involving demand and capital remain for the EV maker....

AI tools could drive $263 billion in holiday sales. Walmart and Target are racing to get in

Consumers are turning to AI chatbots like ChatGPT for gift discovery, reviews and price matching, potentially driving billions in sales this holiday season....

‘The next protein’: Fiber is shaping up to be the latest grocery obsession

As consumers find their next grocery obsession in fiber, food and beverage companies are racing to keep up with the trend....

Homeowners are losing thousands in equity thanks to weakening prices

Weaker prices mean homeowners are starting to lose equity after several years of huge gains....

Lululemon CEO Calvin McDonald to depart in January as retailer struggles to compete, woo shoppers

Lululemon's CEO Calvin McDonald will leave the athleisure retailer at the end of January as sales in its largest market sag and consumers flee to competitors....

Costco tops Wall Street's sales and revenue expectations

Costco on Thursday surpassed Wall Street's quarterly expectations as its sales rose 8.2% year over year....

Rivian announces new AI tech, chip and robotaxi ambitions

The company has also developed AI models to power its Autonomy+ subscription, which it intends to roll out early next year for $2,500 up front or $49.99 a month....

Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. ...